NCT04930887View on ClinicalTrials.gov

Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2030

Conditions
Craniofacial PainMigraineCluster HeadacheTrigeminal Autonomic CephalgiaSphenopalatine Ganglion NeuralgiaParoxysmal Hemicrania
Interventions
DRUG

Exparel (Bupivacaine Liposome)

Non-opioid postsurgical analgesic used in the management of postsurgical pain; 133 mg/10 mL (13.3 mg/mL) single-dose vial (per Pacira), study administers 3cc bilaterally

DRUG

Saline

Prescription medicine used for fluid and electrolyte replenishment for intravenous administration; Exparel-matched Placebo treatment

Trial Locations (1)

94304

RECRUITING

Peter H Hwang, Stanford

All Listed Sponsors
lead

Stanford University

OTHER